Literature DB >> 15352169

Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor.

William R Huckle1, Rebecca I Roche.   

Abstract

Vascular endothelial growth factor (VEGF) is a major modulator of angiogenesis. Biological effects of VEGF are mediated by endothelial cell-surface receptors, KDR and Flt-1. Alternative Flt-1 RNA processing, involving retention of intron 13 and the use of intronic cleavage-polyadenylation signals, produces a secreted form of Flt-1, "sFlt-1," that binds VEGF with high affinity and can inhibit VEGF signaling. To probe mechanisms controlling sFlt-1 expression, we have cloned and sequenced Flt-1 intron 13 from a mouse genomic library and located RNA processing signals potentially involved in sFlt-1 mRNA formation. A minigene construct containing Flt-1 intron 13 directed the expression of both secreted (i.e., cleaved/polyadenylated) and transmembrane (i.e., spliced) forms of Flt-1 mRNA and protein. Using rapid amplification of 3' cDNA ends (3'-RACE) and quantitative PCR (QPCR) analysis to test the activity of intronic cleavage-polyadenylation signals, we observed that multiple sites were utilized for sFlt-1 mRNA processing in both native tissues and Flt-1 minigene transfectants. In transfectants, the most distal signal was utilized preferentially. The potential for interaction between pathways leading to sFlt-1 or full-length Flt-1 was evaluated using QPCR to measure relevant mRNAs after transfection with signal mutants. Decreased expression of sFlt-1 mRNA in cleavage-polyadenylation mutants was accompanied by reciprocal increases in full-length Flt-1 mRNA. Multiple sFlt-1 mRNA species are formed that differ by up to 3.9 kb in their 3'-untranslated regions (UTRs), which contain sites of potential regulatory importance. The reciprocity between sFlt-1 and Flt-1 mRNA expression suggests a novel post-transcriptional mechanism by which sFlt-1 protein production and, thereby, responsiveness to VEGF, may be modulated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352169     DOI: 10.1002/jcb.20142

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  23 in total

1.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

Review 2.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

3.  Preeclampsia and soluble fms-like tyrosine kinase 1.

Authors:  James M Roberts; Augustine Rajakumar
Journal:  J Clin Endocrinol Metab       Date:  2009-07       Impact factor: 5.958

4.  Placental Nkx2-5 and target gene expression in early-onset and severe preeclampsia.

Authors:  Elena R Rivers; Anthony J Horton; Angela F Hawk; Elizabeth G Favre; Katherine M Senf; Paul J Nietert; Eugene Y Chang; Ann C Foley; Christopher J Robinson; Kyu-Ho Lee
Journal:  Hypertens Pregnancy       Date:  2014-07-02       Impact factor: 2.108

Review 5.  Angiogenic factors in preeclampsia and related disorders.

Authors:  Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

6.  Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia.

Authors:  Jennifer L Sones; Audrey A Merriam; Angelina Seffens; Dex-Ann Brown-Grant; Scott D Butler; Anna M Zhao; Xinjing Xu; Carrie J Shawber; Jennifer K Grenier; Nataki C Douglas
Journal:  FASEB J       Date:  2018-01-08       Impact factor: 5.191

7.  Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model.

Authors:  Yang Kyung Cho; Hironori Uehara; Jason R Young; Bonnie Archer; Xiaohui Zhang; Balamurali K Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

8.  Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.

Authors:  Snehal Naik; Robin S Dothager; Jayne Marasa; Cory L Lewis; David Piwnica-Worms
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Jason R Young; Bonnie Archer; Balamurali Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-19       Impact factor: 4.799

10.  TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1.

Authors:  Jian-Wei Qi; Ting-Ting Qin; Li-Xia Xu; Kun Zhang; Gui-Li Yang; Jie Li; Huai-Yuan Xiao; Zhi-Song Zhang; Lu-Yuan Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.